Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

Cyclical, high-dose testosterone administration, termed bipolar androgen therapy (BAT), can induce clinical responses and restore sensitivity to androgen signalling inhibition in patients with previously treated castration-resistant prostate cancer (PCa) (CRPC). This trial evaluated whether BAT is a safe and effective first-line hormonal therapy for patients with CRPC.

Source: European Journal of Cancer - December 29, 2020 Category: Cancer & Oncology Authors: Laura A. Sena, Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs, Jun Luo, Caroline Pratz, Victoria Sinibaldi, Michael A. Carducci, Channing J. Paller, Mario A. Eisenberger, Mark C. Markowski, Emmanuel S. Antonarakis, Samuel R. Denmeade Tags: Original Research Source Type: research